John Arena, interim president of global pharma services at Cencora, discusses the importance of engaging with partners as ...

Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

The campaign is based on the results of a survey that reveals the experiences of patients and caregivers in their communities ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Valencia will seek to leverage the investment as well as Surek’s leadership experience to drive commercialization of its ...

Led by Bosch Ventures, Applyo Jena’s Series A funding seeks to accelerate the development and commercialization of its ...

Last week, the Trump administration ordered all federal agencies to lay off all probationary workers. As a result, hundreds ...

Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.

James Foster, CEO and co-founder of Virax Biolabs, discusses how global launches are being impacted by changing geopolitical ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about how the recent NASDAQ ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...